<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085982</url>
  </required_header>
  <id_info>
    <org_study_id>030257</org_study_id>
    <secondary_id>03-DK-0257</secondary_id>
    <nct_id>NCT00085982</nct_id>
  </id_info>
  <brief_title>Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance</brief_title>
  <official_title>Phase II Trial of Effect of Metreleptin Therapy in Severe Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Description:&#xD;
&#xD;
      Patients with mutations of the insulin receptor have diabetes that is challenging to control&#xD;
      withconventional therapies, leading to early morbidity and mortality. We hypothesize that&#xD;
      recombinant leptin (metrel eptin) in these patients will improve glycemia control.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary Objective: To determine if 1 year of metreleptin will improve glycemia control in&#xD;
      patients with genetic defects of the insulin receptor. Secondary Objectives: To determine&#xD;
      mechanisms by which metreleptin improves glycemia.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary Endpoint: Hemoglobin A1c.&#xD;
&#xD;
      Secondary Endpoints: fasting plasma glucose, fasting insulin/C-peptide,&#xD;
      glucose/insulin/C-peptide area under the curve during oral glucose tolerance test.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      20 male or female patients with mutations of the insulin receptor, age (Bullet)5 years, at&#xD;
      the NIH Clinical Center.&#xD;
&#xD;
      Description of Sites/Facilities Enrolling Participants: Description of Study Intervention:&#xD;
&#xD;
      NIH Clinical Center&#xD;
&#xD;
      Open label study of metreleptin, 0.2 mg/kg/day (max dose 0.24 mg/kg/day).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Description:&#xD;
&#xD;
      Patients with mutations of the insulin receptor have diabetes that is challenging to control&#xD;
      withconventional therapies, leading to early morbidity and mortality. We hypothesize that&#xD;
      recombinant leptin (metrel eptin) in these patients will improve glycemia control.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary Objective: To determine if 1 year of metreleptin will improve glycemia control in&#xD;
      patients with genetic defects of the insulin receptor. Secondary Objectives: To determine&#xD;
      mechanisms by which metreleptin improves glycemia.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary Endpoint: Hemoglobin A1c.&#xD;
&#xD;
      Secondary Endpoints: fasting plasma glucose, fasting insulin/C-peptide,&#xD;
      glucose/insulin/C-peptide area under the curve during oral glucose tolerance test.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      20 male or female patients with mutations of the insulin receptor, age (Bullet)5 years, at&#xD;
      the NIH Clinical Center.&#xD;
&#xD;
      Description of Sites/Facilities Enrolling Participants: Description of Study Intervention:&#xD;
&#xD;
      NIH Clinical Center&#xD;
&#xD;
      Open label study of metreleptin, 0.2 mg/kg/day (max dose 0.24 mg/kg/day).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2003</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvements in HbA1C, fasting blood glucose, &amp;amp; fasting insulin levels</measure>
    <time_frame>every 6-12 months</time_frame>
    <description>Lower HbA1C, lower blood glucose values, &amp;amp; lower insulin levels.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Leptin Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of study drug administered via SC injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metreleptin</intervention_name>
    <description>Administered SQ twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation</description>
    <arm_group_label>Leptin Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Male or female, aged &gt; 5 years&#xD;
&#xD;
          -  Clinically significant, severe insulin resistance caused by a known or suspected&#xD;
             defect in the insulin receptor&#xD;
&#xD;
          -  Presence of at least one of the following metabolic abnormalities:&#xD;
&#xD;
               -  Fasting insulin &gt;30 micro U/ml, or&#xD;
&#xD;
               -  Presence of diabetes as defined by the 2006 ADA criteria:&#xD;
&#xD;
                    -  Fasting plasma glucose &gt;= 126 mg/dL&#xD;
&#xD;
                    -  2 hour plasma glucose &gt;= 200 mg/dL following a 75 gram (1.75g/kg if less&#xD;
                       than 40kg) oral glucose load, or&#xD;
&#xD;
                    -  Diabetic symptoms with a random plasma glucose &gt;= 200 mg/dL&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Pregnant at time of enrollment, women in their reproductive years who do not use an&#xD;
             effective method of birth control, and women currently nursing or lactating within 6&#xD;
             weeks of having completed nursing.&#xD;
&#xD;
          -  Known infectious liver disease&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Current alcohol or substance abuse&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Use of anorexiogenic drugs&#xD;
&#xD;
          -  Other conditions which in the opinion of the clinical investigators would impede&#xD;
             completion of the study.&#xD;
&#xD;
          -  Subjects who have a known hypersensitivity to E. Coli derived proteins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca J Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan S Startzell, R.N.</last_name>
    <phone>(301) 402-6371</phone>
    <email>megan.startzell@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca J Brown, M.D.</last_name>
    <phone>(301) 594-0609</phone>
    <email>brownrebecca@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2003-DK-0257.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Sekizkardes H, Chung ST, Chacko S, Haymond MW, Startzell M, Walter M, Walter PJ, Lightbourne M, Brown RJ. Free fatty acid processing diverges in human pathologic insulin resistance conditions. J Clin Invest. 2020 Jul 1;130(7):3592-3602. doi: 10.1172/JCI135431.</citation>
    <PMID>32191645</PMID>
  </reference>
  <verification_date>July 28, 2021</verification_date>
  <study_first_submitted>June 18, 2004</study_first_submitted>
  <study_first_submitted_qc>June 18, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2004</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rabson Mendenhall</keyword>
  <keyword>Type B Insulin Resistance</keyword>
  <keyword>Type A Insulin Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 15, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

